Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment

Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment

-

Bibliographic Details
Main Author:	Bruno Balbi
Format:	Article
Language:	English
Published:	PAGEPress Publications 2015-08-01
Series:	Monaldi Archives for Chest Disease
Subjects:	COPD Pharmacological treatment LABA LAMA ICS Roflumilast
Online Access:	https://www.monaldi-archives.org/index.php/macd/article/view/26

Similar Items

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment
by: Ita Octafia, et al.
Published: (2021-01-01)

Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
by: Moretz C, et al.
Published: (2020-09-01)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
by: Moretz C, et al.
Published: (2019-08-01)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
by: Singh D, et al.
Published: (2019-12-01)

The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol
by: Richeldi L, et al.
Published: (2021-01-01)

The use of roflumilast in COPD: a review
by: Andrea Zanini, et al.
Published: (2015-08-01)

Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored
by: Vitalii I. Kupaev, et al.
Published: (2020-06-01)

Early COPD diagnosis and treatment: A case report
by: Roberto G. Carbone, et al.
Published: (2023-01-01)

The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study
by: Tarek M. Mostafa, et al.
Published: (2021-01-01)

Significant gas-exchange improvements reported after roflumilast in two cases of severe COPD
by: Bruno Sposato
Published: (2015-08-01)

Optimizing bronchodilation in the prevention of COPD exacerbations
by: Marc Miravitlles, et al.
Published: (2017-06-01)

Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study
by: Soler-Cataluña JJ, et al.
Published: (2023-06-01)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
by: Yamada H, et al.
Published: (2018-10-01)

LA inhalers for COPD: perceptions/reality of ABCD GOLD tool use
by: Varvara Boryushkina, et al.
Published: (2020-07-01)

Roflumilast succeeds where traditional therapy fails: a case report
by: Gabriella Guarnieri
Published: (2015-08-01)

Roflumilast is effective in reducing COPD related exacerbations and improving CAT score
by: Biagio Polla
Published: (2015-08-01)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
by: Marc Miravitlles, et al.
Published: (2022-11-01)

Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada
by: Tavakoli H, et al.
Published: (2019-09-01)

Day and Night Control of COPD and Role of Pharmacotherapy: A Review
by: Braghiroli A, et al.
Published: (2020-06-01)

A case report of roflumilast in an elderly COPD patient: improving exercise capacity to improve quality of life
by: Daniela Parola, et al.
Published: (2015-08-01)

GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting
by: Yawn BP, et al.
Published: (2021-02-01)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
by: Bourbeau J, et al.
Published: (2021-03-01)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
by: Micheletto C, et al.
Published: (2019-09-01)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
by: Yang HH, et al.
Published: (2017-08-01)

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
by: Buhl R, et al.
Published: (2020-10-01)

Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?
by: Paolo Solidoro, et al.
Published: (2022-03-01)

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014
by: Josefin Sundh, et al.
Published: (2017-01-01)

Roflumilast – a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD
by: Anne B Taegtmeyer, et al.
Published: (2012-07-01)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
by: Rogliani P, et al.
Published: (2018-10-01)

Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis
by: Marc Miravitlles, et al.
Published: (2022-12-01)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
by: Kalhan R, et al.
Published: (2021-04-01)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
by: Derom E, et al.
Published: (2016-12-01)

Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis?
by: Mette Gyldenløve, et al.
Published: (2022-08-01)

Longstanding tracheobronchomalacia: A forgotten cause of severe cough and its response to roflumilast
by: Veronica Ann Varney, et al.
Published: (2020-01-01)

Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
by: Imane Achir Alispahic, et al.
Published: (2020-05-01)

Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice
by: S. Vamsee Raju, et al.
Published: (2017-09-01)